
Natco Pharma (NATCOPHARM) Share Price hits fresh 52-week low at Rs 780
Updated: 15 Oct 2026 • 9:24 am
Posted by:

Natco Pharma Share Price is in focus after Natco Pharma Ltd. (NATCOPHARM) touched a fresh 52-week low of Rs 780 and last traded at Rs 784.90, up 0.24% from the previous close of Rs 783. According to Univest data, the company’s market capitalisation stood at Rs 15,489.42 crore, placing the move in the context of a listed healthcare business with a sizeable equity base. Natco Pharma Share Price, Natco Pharma Share Price Today and Natco Pharma Stock News are drawing attention because the stock is at a new yearly low even though the current trade is slightly above the day’s low. According to Univest data, the price event is confirmed, but no company-specific catalyst is established. In that setting, Natco Pharma Share Price is best read through the day’s range, its valuation and the sector benchmark rather than through unsupported cause-and-effect claims.
Natco Pharma Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 784.9 |
| Previous Close | Rs 783 |
| Today's Move | +Rs 1.9 (+0.24%) |
| Open | Rs 783 |
| High | Rs 787.75 |
| Low | Rs 780 |
| Market Capitalisation | Rs 15,489.42 crore |
Natco Pharma Ltd. (NATCOPHARM) traded at Rs 784.9 versus the previous close of Rs 783, a rise of 0.24%. The stock opened at Rs 783, reached a high of Rs 787.75, touched a low of Rs 780.
Natco Pharma Share Price today moved between Rs 780 and Rs 787.75, with the stock opening at Rs 783, touching a low of Rs 780 and a high of Rs 787.75. The current price of Rs 784.90 is Rs 1.90 above the previous close, which reflects a 0.24% rise at the time of writing. The fresh 52-week low of Rs 780 is also the day’s low, so the yearly low and the intraday trough match. For Natco Pharma Share Price, that combination matters because it shows where the market is trading right now relative to the new low, without implying any unverified trigger. Natco Pharma Share Price Live action will remain important through the rest of the market session, especially if it stays near the Rs 780 to Rs 787.75 band. Natco Pharma Share Price news is therefore about the price event itself, and the next natural step is to place that move against fundamentals.
Natco Pharma Share Price also needs to be viewed alongside the company’s market capitalisation of Rs 15,489.42 crore, which frames the stock as a meaningful name within Indian healthcare. The gap between the day’s low and high is narrow, so Natco Pharma Share Price update remains tightly linked to the opening range and the fresh 52-week low rather than to a broader swing.
Natco Pharma Ltd. (NATCOPHARM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 15,489.42 crore |
| P/E Ratio | 13.42x |
| P/B Ratio | 1.64x |
| ROE | 16.3% |
| ROCE | 17.16% |
| EPS | Rs 58.33 |
| Book Value Per Share | Rs 476.47 |
| Dividend Yield | 0.63% |
Natco Pharma Ltd. (NATCOPHARM) fundamental metrics show P/E 13.42x, P/B 1.64x, ROE 16.3%, ROCE 17.16%. These figures provide context only and are not a buy or sell signal.
Natco Pharma Ltd. has a market capitalisation of Rs 15,489.42 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 13.42x, P/B at 1.64x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 16.3% and ROCE of 17.16%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 58.33, book value per share of Rs 476.47, dividend yield of 0.63%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.4x, median ROE of 11.53%, median ROCE of 13.32%. Taken together, they outline the fundamentals rather than a view on the stock.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 13.42x |
| Benchmark Median P/E | 31.4x |
| Benchmark Average P/E | 47.12x |
| Benchmark P/E Range | 3.13x to 654.72x |
| Company P/B Ratio | 1.64x |
| Benchmark Median P/B | 2.85x |
| Company ROE | 16.3% |
| Benchmark Median ROE | 11.53% |
| Company ROCE | 17.16% |
| Benchmark Median ROCE | 13.32% |
| Company Market Capitalisation | Rs 15,489.42 crore |
| Benchmark Median Market Cap | Rs 808.34 crore |
Natco Pharma Ltd. (NATCOPHARM) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.42x, which is below the benchmark median of 31.4x, a difference of -57.26%. On its own, the P/E gap is a valuation reference point, not a trading call.
Natco Pharma Ltd. (NATCOPHARM) has a ROE of 16.3%, which is above the benchmark median of 11.53%, a difference of +41.37%. Natco Pharma Ltd. (NATCOPHARM) has a ROCE of 17.16%, which is above the benchmark median of 13.32%, a difference of +28.83%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Ltd. | APLLTD | 15,668.05 | 22.46 | 2.66 | 12.35 | 11.74 |
| Eris Lifesciences Ltd. | ERIS | 15,955.63 | 24.76 | 3.95 | 19.23 | 14.47 |
| Jubilant Pharmova Ltd. | JUBLPHARMA | 15,019.42 | 42.48 | 2.1 | 5.97 | 8.69 |
| Astrazeneca Pharma India Ltd. | ASTRAZEN | 14,858.75 | 87.6 | 16.43 | 23.02 | 31.24 |
| Glenmark Life Sciences Ltd. | ALIVUS | 16,502.32 | 27.37 | 4.74 | 18.41 | 24.61 |
Natco Pharma Ltd. (NATCOPHARM) has a P/E ratio of 13.42x compared with the displayed peer median of 27.37x. This peer read is a relative benchmark rather than a trading signal. Its ROE of 16.3% compares with a peer median of 18.41% across the companies shown in the table. ROCE stood at 17.16% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Natco Pharma Ltd. (NATCOPHARM) has a market capitalisation of Rs 15,489.42 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Why Investors Are Watching Natco Pharma
- Natco Pharma Share Price has touched a fresh 52-week low of Rs 780 and is trading near that level.
- The current Natco Pharma Share Price of Rs 784.90 is only slightly above the previous close of Rs 783.
- Natco Pharma Share Price carries a P/E ratio of 13.42 and a P/B ratio of 1.64, both below the sector benchmark median.
- ROE of 16.3% and ROCE of 17.16% place Natco Pharma Share Price above the sector median on return metrics.
- Natco Pharma Share Price remains in focus because its market cap of Rs 15,489.42 crore sits meaningfully above the sector median.
About Natco Pharma
Natco Pharma Ltd. operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. Natco Pharma Share Price reflects a company whose business is tied to the development, manufacturing and sale of pharmaceutical products, which is the operating context used by the market for this listed name. The company’s financial profile for the latest quarter shows revenue of Rs 735.2 crore for Jun 2026, while the latest equity metrics include EPS of Rs 58.33, book value of Rs 476.47 and dividend yield of 0.63%.
For Natco Pharma Share Price, that company context matters because investors often compare the stock not only with peer valuation but also with how efficiently the business turns capital into returns. The current market capitalisation of Rs 15,489.42 crore gives a size reference, while the P/E ratio of 13.42 and ROCE of 17.16% provide a basic fundamental frame. Natco Pharma Stock News around a 52-week low is therefore best read as a valuation-and-performance checkpoint inside the healthcare landscape.
Track Natco Pharma Share Price on Univest
Use Natco Pharma Ltd. (NATCOPHARM) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.
Natco Pharma Share Price can be tracked on Univest for live price movement, market capitalisation, valuation ratios, one-year low levels and company fundamentals. Univest also brings Natco Pharma Stock News, Natco Pharma Share Price Today updates and Natco Pharma Latest News together in one place. For readers following Natco Pharma Share Price after the fresh 52-week low, that gives a simple way to monitor the next price update, the latest ratios and the broader market context without mixing it with opinion.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why did Natco Pharma Share Price touch a fresh 52-week low?
Ans. According to Univest data, the stock touched Rs 780, which is the fresh 52-week low, but no company-specific catalyst is established. The price action is best understood through the day’s range, valuation and sector comparison.
What is Natco Pharma Share Price today?
Ans. Natco Pharma Share Price is Rs 784.90 at the time of writing, up Rs 1.90 or 0.24% from the previous close of Rs 783. It is trading just above the day’s low of Rs 780.
What is the fresh 52-week low for Natco Pharma?
Ans. The fresh 52-week low for Natco Pharma Share Price is Rs 780. That level is also the day’s low, so the one-year low and the intraday trough are the same in this market update.
How is Natco Pharma Share Price valued versus the sector?
Ans. Natco Pharma Share Price trades at a P/E of 13.42 and a P/B of 1.64, both below the sector benchmark median. ROE of 16.3% and ROCE of 17.16% stand above the benchmark median.
What does Natco Pharma’s market cap say?
Ans. Natco Pharma Share Price is backed by a market capitalisation of Rs 15,489.42 crore. That places the company above the sector median market cap and close to the upper end of the benchmark range.
How strong are Natco Pharma’s returns on capital?
Ans. Natco Pharma Share Price is supported by ROE of 16.3% and ROCE of 17.16%. Both are higher than the sector benchmark median, which gives the stock a useful return profile for comparison.
What are Natco Pharma’s EPS and book value?
Ans. Natco Pharma Share Price comes with EPS of Rs 58.33 and book value of Rs 476.47 per share. EPS shows earnings per share, while book value reflects the accounting net worth behind each share.
How does Natco Pharma compare with peers?
Ans. Natco Pharma Share Price has a lower P/E than listed peers such as Alembic Pharmaceuticals, Eris Lifesciences and Glenmark Life Sciences. Its market cap also sits within the peer band shown in the comparison set.
What should readers monitor next in Natco Pharma Share Price?
Ans. Readers can monitor whether Natco Pharma Share Price stays near Rs 780 or moves back toward the day’s high of Rs 787.75. The next update should also be read alongside valuation and sector context.
Recent Articles

Why KPI Green Energy Shares and Waaree Energies Shares Are Rising Today: Prices, the Reported Rs 15,000 Crore Green Ammonia Plan, Q2 and Q1 Numbers, and What Is and Is Not Confirmed
11 November 2026

US AI Sell-Off: Are Indian AI Stocks Next? What Fell on 6 November, Why Nifty IT Rose, How Netweb and E2E Were Hit, and Which Risks and Dates to Watch Before Drawing Conclusions
11 November 2026

Railway Stocks Rally: RVNL and IRFC Jump Up to 10% as Sensex and Nifty Rise, What the Moves Look Like Against a 25% to 32% One-Year Fall, and What Is Not Yet Known
11 November 2026

Ashoka Buildcon Shares Soar 14% After Rs 865.90 Crore NHAI Order: Contract Details, Q2 Loss of Rs 118.96 Crore, Order Book and Debt, and Why the Stock Is Still Down Over a Year
11 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Why KPI Green Energy Shares and Waaree Energies Shares Are Rising Today: Prices, the Reported Rs 15,000 Crore Green Ammonia Plan, Q2 and Q1 Numbers, and What Is and Is Not Confirmed
US AI Sell-Off: Are Indian AI Stocks Next? What Fell on 6 November, Why Nifty IT Rose, How Netweb and E2E Were Hit, and Which Risks and Dates to Watch Before Drawing Conclusions
Railway Stocks Rally: RVNL and IRFC Jump Up to 10% as Sensex and Nifty Rise, What the Moves Look Like Against a 25% to 32% One-Year Fall, and What Is Not Yet Known
Ashoka Buildcon Shares Soar 14% After Rs 865.90 Crore NHAI Order: Contract Details, Q2 Loss of Rs 118.96 Crore, Order Book and Debt, and Why the Stock Is Still Down Over a Year
IndiGo Share Price Jumps 5% as Top Nifty 50 Gainer: Crude Relief, the Q2 Loss, What Brokerages Say on IndiGo Target Price and Upside, and the Risks to Weigh
Popular this week
TD Power Shares Jump 5% as Sensex and Nifty Rally Ahead of Q2 Results on 12 November: The 350% Three-Year Run, the Recent Slide and What the Q1 Base Says

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





